Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (1108)	12/29/1998 3:14:00 PM
From: Red Dragon	Respond to of 1115

In retrospect, all the warning signs were there for at least 1-2 years as detailed in my earlier posts. Message 3215082 Message 3107874 Message 3136811 Lidakol is completely ineffective. It is the same as placebo. Period. Through statistical manipulation and clever, deceptive language, they made Lidakol seem promising. They were very good at it - only those with a skeptical mind and training in biosciences and statistics could see through the deception. I urged investors to cut losses and get out. I predicted that the FDA would not approve the drug and that the stock would then slowly slip to zero. I believe that a lawsuit is potentially justifiable based on the company's long history of deception. But as I pointed out a year ago, there will be nothing to sue for. Maybe AVNR can raise a few bucks by selling off office furniture... One last gasp of deception. The company says they are only one trial away from approval. Yeah, right. If a huge 100,000 patient multicenter trial showed that Lidakol was extremely efficacious, they would get FDA approval. It ain't going to happen. I took a lot of heat for being negative on this stock - at times I was the only negative voice. That's okay, that's the purpose of this forum. Let's all learn from this. Blind faith can be dangerous. If someone offers objective, factual analysis, we should listen carefully and be willing to suspend our faith. It may not be a bad idea to read through my posts above, as well as other messages I posted around that time in which I pick Lidak to pieces. Don't make this a total loss. Try and learn from it. If you have trouble understanding the statistical points, my best advice is to not invest in biotech stocks. Better luck to all in future investments. This one's over.

To: Henry Niman who wrote (1108)	1/14/1999 10:52:00 AM
From: Henry Volquardsen	Respond to of 1115

YAKATAN GERALD J,C.E.O.,BUYS 17,500 ON 12/30/98 OF AVANIR PHARMA 1/14/99 7:41 FORM 4 SEC - ON 12/30/98, YAKATAN GERALD J, CHIEF EXECUTIVE OFFICER OF AVANIR PHARMACEUTICALS (TICKER:AVNR) BOUGHT 17,500 SHARES AT $0.56, BRINGING HOLDINGS TO 37,500 SHARES. The Washington Service reports only purchases and sales (both open market and private) of common stock. Further information on our services may be obtained by calling (202) 778-1380, or by typing WSA <GO>. (9011303C) -0- (WSA) Jan/14/ 99 7:40

To: Henry Niman who wrote (1108)	1/14/1999 1:34:00 PM
From: Henry Volquardsen	Read Replies (1) \| Respond to of 1115

AVANIR PHARMACEUTICALS REQUESTS MEETING WITH THE FDA 1/14/99 12:32 SAN DIEGO, Jan. 14, /PRNewswire/ -- Avanir Pharmaceuticals (Nasdaq: AVNR), a developer of novel therapeutic products for the treatment of chronic diseases, today filed a formal request for a meeting with the Federal Food and Drug Administration (FDA). The purpose of the meeting will be to discuss the additional data the FDA has requested before it can grant approval of Avanir's New Drug Application (NDA) for docosanol, a topical treatment for oral-facial herpes infections. Following earlier discussions with the FDA, the agency has agreed to grant a meeting within 30 days after the request is received. Gerald J. Yakatan, Ph.D., Avanir's president and chief executive officer said, "We continue to believe that the data submitted in our NDA demonstrates substantial evidence of effectiveness in the treatment of oral-facial herpes. And we will work with the FDA to clarify the additional information they may require." "At this point, we are exploring several options to generate revenue in 1999, including an over-the-counter product that meets existing federal regulatory requirements," concluded Dr. Yakatan. Avanir Pharmaceuticals, based in San Diego, develops novel therapeutic products for the treatment of chronic diseases. The company is also seeking in-licensing agreements with other pharmaceutical companies for late-stage products to complete its drug pipeline. The information contained in this press release, including any forward looking statements contained herein, should be reviewed in conjunction with the Company's Annual Report on Form 10-K and other publicly available information regarding the Company, copies of which are available from the Company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business and such statements, including risks and uncertainties related to drug development and clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside of the influence and/or control of the Company. SOURCE Avanir Pharmaceuticals -0- 01/14/99 /CONTACT: Gregory Hanson, CFO of Avanir Pharmaceuticals, 619-410-2670; or Bob Stone, home - 914-591-5534, or Ken DiPaola, both of The Dilenschneider Group, 212-922-0900, for Avanir Pharmaceuticals/ (AVNR) CO: Avanir Pharmaceuticals; Food and Drug Administration ST: California IN: MTC SU: LEG -0- Jan/14/1999 12:17